NEW DELHI: Human dosing of Bharat Biotech International Ltd’s vaccine candidate ‘covaxin’ against the novel coronavirus started on Wednesday, with the vaccine being given to participants at All India Institute of Medical Sciences, Patna and Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) at Rohtak in Haryana, a spokesperson for the company said in a statement late Friday.“India’s First Indigenous Covid19 Vaccine Covaxin initiated phase-1 clinical trials across the country on 15th July 2020.
This is a randomised, double-blind, placebo-controlled clinical trial in 375 volunteers in India," a spokesperson for Bharat Biotech said in a statement.AIIMS Patna was the first institute to start the trial on Wednesday.